European Cancer Guidelines Add Delcath Liver Therapy for Eye Melanoma

Key Takeaways

• April 2026 ESMO–EURACAN uveal melanoma guideline lists CHEMOSAT M-PHP among regional liver-directed therapies for liver-dominant mUM.
• Supporting Phase 3 IDs cited by Delcath: NCT02678572 and NCT00324727.
• ESMO-MCBS score 3 reported for selected unresectable hepatic-metastasis criteria (<50% liver involvement).
• NCI notes eye melanoma often spreads to the liver; multidisciplinary algorithms now pair M-PHP with systemic options such as tebentafusp by HLA status.

How did European cancer guidelines add Delcath CHEMOSAT?

On April 6, 2026, Delcath announced via Business Wire that CHEMOSAT M-PHP was included in the newly published ESMO–EURACAN Clinical Practice Guideline for uveal melanoma diagnosis, treatment, and follow-up (April 2026).

The guideline recognizes M-PHP under regional treatments for liver-dominant metastatic disease and, per the company release, lists it first among regional options for multifocal liver-only metastases, alone or with systemic therapy depending on HLA-A*02:01 status.

Which Phase 3 datasets underpin the recommendation?

Delcath states the guideline cites NCT02678572 and NCT00324727 as key Phase 3 evidence showing improved hepatic and overall progression-free survival and overall response rates versus best alternative care.

The published guideline DOI is 10.1016/j.esmoop.2026.106888 (ESMO Open). Teams should read the full text and supplements for exact recommendation strength wording rather than relying only on the company summary.

Why does liver-directed therapy matter in uveal melanoma?

The NCI PDQ on intraocular melanoma emphasizes that metastatic eye melanoma frequently involves the liver, making hepatic control central to morbidity and survival discussions.

• Company-cited ESMO-MCBS score 3 for unresectable hepatic metastases <50% of liver with no/limited locally treatable extrahepatic disease
• Positioning alongside tebentafusp and anti-PD-1 options in multidisciplinary algorithms
• Parallel U.S. NCCN Category 2A recognition of HEPZATO KIT / M-PHP for hepatic-dominant mUM (company statement)

What should European access and BD teams do next?

Update EU tender and center-of-excellence maps for percutaneous hepatic perfusion capacity, melphalan logistics, and referral pathways from ocular oncology to interventional radiology. Model sequencing versus tebentafusp in HLA-A*02:01-positive patients and versus other systemic options when M-PHP is used after or instead of systemic therapy.

Guideline inclusion is not the same as national reimbursement. Confirm local HTA and hospital formulary steps country by country even where ESMO–EURACAN language is favorable.

What remains unproven after guideline inclusion?

Real-world DFS/OS outside Phase 3 populations, center learning curves, and combination toxicity with contemporary systemic agents are not fully settled by guideline text alone. Do not invent ORR percentages beyond what the cited trials and guideline tables show. Treat the Business Wire MCBS score claim as company-reported pending verification in the published supplement.

European hospital systems also differ in interventional radiology capacity and melphalan handling infrastructure, so guideline text will not automatically equal equal access in every Member State. Competitive intelligence should track whether centers publish protocolized pathways that combine M-PHP with tebentafusp or checkpoint inhibitors, and whether payers demand additional local outcomes data beyond the Phase 3 IDs already cited. Until those adoption metrics appear in registries or HTA dossiers, model European revenue upside as staged by country rather than as a single ESMO-driven step-change. Watch 2026–2027 referral volumes at early-adopter centers for confirmation of clinical uptake trends.

Related NovaPharma coverage

• Notable oncology FDA approvals May 2026
• EU informed consent research template for trials
• Gilead Hepcludex FDA approval hepatitis D

Frequently Asked Questions

Primary Sources

1. Business Wire: Delcath CHEMOSAT in ESMO–EURACAN guidelines
2. DOI: ESMO–EURACAN uveal melanoma Clinical Practice Guideline
3. ClinicalTrials.gov: NCT02678572
4. ClinicalTrials.gov: NCT00324727
5. NCI PDQ: Intraocular (uveal) melanoma treatment